The New England journal of medicine
-
Comment Randomized Controlled Trial
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, reduced albuminuria in short-term trials involving patients with chronic kidney disease (CKD) and type 2 diabetes. However, its long-term effects on kidney and cardiovascular outcomes are unknown. ⋯ In patients with CKD and type 2 diabetes, treatment with finerenone resulted in lower risks of CKD progression and cardiovascular events than placebo. (Funded by Bayer; FIDELIO-DKD ClinicalTrials.gov number, NCT02540993.).
-
Letter Case Reports
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host.
-
Historical Article
Solving Population-wide Obesity - Progress and Future Prospects.